Posted On: Jun-2026 | Categories : Healthcare
Cancer treatment has improved sharply over the past decade, but one problem keeps returning across oncology: tumors learn how to survive therapy. A patient may respond to chemotherapy, targeted therapy, or immunotherapy at first, yet the disease can later adapt through alternative survival pathways, immune escape, or metastatic behavior. This is where AXL has become more than another receptor tyrosine kinase target.
AXL is now being studied because it sits close to several mechanisms that make cancers harder to treat. It has been linked to epithelial-mesenchymal transition, invasion, metastasis, immune suppression, angiogenesis, stem-like tumor behavior, and acquired drug resistance. That makes the AXL inhibitors market different from conventional targeted-therapy markets. The commercial story is not built around one mutation or one biomarker-defined tumor. It is built around the harder question of whether resistance biology itself can be drugged.
Many successful oncology drugs are built around clear genomic drivers. EGFR inhibitors, ALK inhibitors, HER2 therapies, and BRAF inhibitors work because a defined alteration creates a treatment entry point. AXL is different. It is often overexpressed or activated through the tumor microenvironment rather than driven by a single common mutation.
That distinction matters commercially. AXL-targeting drugs cannot rely only on a simple mutation-test model. They need evidence that AXL expression, pathway activation, tumor phenotype, or immune context identifies patients who are more likely to benefit. This has made clinical development slower but also more strategically interesting.
The most attractive use case is not broad AXL inhibition across all cancers. It is selective intervention in tumors that have become invasive, drug-tolerant, immune-resistant, or poorly responsive to standard therapies. That is why AXL keeps appearing in studies involving non-small cell lung cancer, colorectal cancer, ovarian cancer, renal cell carcinoma, gastric cancer, pancreatic cancer, sarcoma, and other difficult-to-treat tumors.
Most AXL programs are not trying to replace frontline oncology standards. They are trying to improve outcomes where current standards are incomplete. This makes the market more clinically specific than a simple “new cancer drug class” story.
In lung cancer, AXL has drawn attention because it may contribute to resistance after targeted therapy and immunotherapy. In HER2-aberrant lung and gastric cancers, newer research has shown that AXL activation can help tumor cells survive HER2-targeted tyrosine kinase pressure. That positions AXL as a potential resistance partner rather than a standalone driver.
In immunotherapy, AXL is relevant because it may support an immune-suppressive tumor environment. The most interesting hypothesis is that AXL blockade could make selected tumors more responsive to PD-1 or PD-L1 inhibition. This is especially important in tumors where checkpoint inhibitors are active but not durable enough.
If AXL inhibition can convert a resistant tumor into a more treatment-sensitive tumor, the class may find a role in combination oncology.
Bemcentinib has been one of the most visible selective AXL inhibitor programs. It helped define the early clinical narrative around AXL inhibition, especially in non-small cell lung cancer and immune-checkpoint combinations. The scientific rationale was strong: AXL inhibition could reduce resistance mechanisms and support antitumor immune activity in selected tumors.
However, the program also shows why the AXL market is difficult. BerGenBio discontinued its first-line STK11-mutated non-small cell lung cancer study in 2025 and began exploring strategic alternatives. That does not invalidate the AXL target, but it does show that biological rationale is not enough. The next stage of AXL development needs stronger patient selection, more reliable biomarkers, and clearer proof that the drug is changing clinical outcomes.
This is an important market lesson. AXL inhibitors will not advance simply because AXL is involved in resistance. They must show which resistant tumors remain dependent on AXL and which combinations produce a measurable survival or response advantage.
Zanzalintinib is not a selective AXL inhibitor. It is a broader kinase inhibitor targeting TAM kinases, including AXL, as well as MET and VEGF receptors. Still, it is one of the most important current signals for the market because it brings AXL-related biology closer to a regulatory-stage commercial discussion.
The FDA accepted Exelixis’ New Drug Application for zanzalintinib plus atezolizumab in previously treated metastatic colorectal cancer. This matters because colorectal cancer has been difficult territory for immunotherapy outside biomarker-defined subgroups. A therapy that combines immune modulation, angiogenesis biology, MET signaling, and TAM kinase inhibition could create a new late-line strategy if the survival signal is strong enough.
From a market perspective, zanzalintinib also shows that AXL may not always win as a single-target strategy. In some tumors, AXL may be most useful as part of a multi-pathway resistance-control approach. That could shift the AXL inhibitors market away from pure kinase selectivity and toward combination-ready agents that act across overlapping resistance networks.
Small-molecule inhibitors are not the only route. AXL-targeted antibodies, soluble receptors, and antibody-drug conjugates are also being explored. These formats ask a different commercial question: can AXL expression be used as a delivery handle or immune-modulation point rather than only as a kinase-signaling target?
Mecbotamab vedotin is an example of this shift. It is an AXL-targeting antibody-drug conjugate designed to bind under acidic tumor-microenvironment conditions and deliver a cytotoxic payload to AXL-expressing tumors. This approach tries to address a core challenge in AXL drug development: AXL is not limited to cancer cells, so conventional targeting can raise toxicity concerns. A conditionally active ADC format attempts to improve tumor selectivity.
Batiraxcept also illustrates the complexity of the field. The Phase 3 AXLerate-OC study in platinum-resistant ovarian cancer did not meet its primary endpoint, but later analyses suggested that patients with high tumor AXL expression may represent a more responsive subgroup. This is exactly where the market is heading: away from broad enrollment and toward biomarker-defined development.
AXL is scientifically attractive because it appears across many aggressive cancer states. That same breadth is also a problem. A target that appears everywhere can become difficult to translate unless clinical trials define where it truly matters.
The future of AXL inhibitors will depend on biomarkers that separate AXL expression from AXL dependency. High AXL staining may not always mean the tumor needs AXL to survive. A more useful approach may combine AXL expression with EMT status, immune-exclusion markers, STK11 alteration, HER2-TKI resistance patterns, soluble AXL, GAS6 signaling, or tumor microenvironment features.
This is why the next wave of AXL trials should not be judged only by asset count. The stronger signal will come from trials that show why a patient was selected and how AXL inhibition changed the treatment outcome.
The market does not need more generic claims that AXL is involved in metastasis and resistance. That part is already established. What it needs is cleaner clinical proof.
First, developers need patient-selection models that identify AXL-relevant tumors before treatment. Second, combinations must be rational rather than additive for the sake of adding another drug. Third, trials must show that AXL inhibition improves outcomes beyond chemotherapy, checkpoint inhibitors, VEGF inhibitors, ADCs, or targeted therapies already available in the same setting.
The most credible near-term direction is combination oncology. AXL inhibition may be most valuable when paired with checkpoint blockade, HER2-targeted therapy, chemotherapy, VEGF/MET inhibition, or ADC-based treatment. In that role, AXL drugs do not need to become universal cancer therapies. They need to solve a defined resistance problem in a defined patient group.
The AXL inhibitors market is entering a more disciplined phase. Early enthusiasm was driven by the target’s broad role in aggressive cancer biology. Current interest is more selective and more evidence-driven. The field is learning that AXL is not simply a target to block; it is a resistance pathway that must be clinically mapped.
Zanzalintinib’s regulatory progress, mecbotamab vedotin’s ADC approach, biomarker signals from batiraxcept, and ongoing translational research in HER2-resistant and immunotherapy-resistant tumors all suggest that AXL remains commercially relevant. The next successful product may not be the most selective AXL inhibitor. It may be the one that best connects AXL biology to a resistant tumor setting where physicians already need a better option.